Home » FDA Partially Grants Petition on Generic Opioid Testing

FDA Partially Grants Petition on Generic Opioid Testing

April 5, 2017

The FDA partially granted a petition filed on behalf of Purdue Pharma concerning generic versions of an extended-release opioid.

To View This Article:

Login

06Jun
Gene & Cell Therapy Regulation: Comparability and Other New Developments
07Jun
Developing World-Class SOPs: Optimizing Quality and Compliance
08Jun
Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures
13Jun
Winners Only: 3 Steps to Compete in Digital Quality
14Jun
Pharmaceutical Quality Risk Management and ICH Q9(R1): Navigating the Global Intersection of Principle and Regulation
20Jun
What’s CSA? And how can it streamline your GxP System Verification?

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements